Open access
Open access
Powered by Google Translator Translator

HIV

Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019.

16 Sep, 2022 | 12:50h | UTC

Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019 – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Systematic Review | Association of HIV infection with cardiovascular pathology based on advanced cardiovascular imaging.

15 Sep, 2022 | 13:02h | UTC

Association of HIV Infection With Cardiovascular Pathology Based on Advanced Cardiovascular Imaging: A Systematic Review – JAMA (free for a limited period)

Editorial: HIV, Subclinical Cardiovascular Disease, and Clinical Progression: Insights From Immunologic Heterogeneity – JAMA (free for a limited period)

 


Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomized ODYSSEY trial.

8 Sep, 2022 | 14:33h | UTC

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial – The Lancet HIV

 

Commentary on Twitter

 


Cohort Study | Dolutegravir in pregnancy as compared with current HIV regimens.

1 Sep, 2022 | 11:55h | UTC

Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States – New England Journal of Medicine (link to abstract – $ for full-text)

Related:

RCT | 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy.

WHO Recommends Dolutegravir as Preferred HIV Treatment Option in All Populations

Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.

RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

Randomized controlled trial compared three antiretroviral regimens started in pregnant women with HIV

Randomized Trial: Switching to Dolutegravir/Lamivudine Two-Drug Regimen Noninferior to Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1

 

Commentary on Twitter

 


M-A | Incidence and mortality of non-AIDS-defining cancers among people living with HIV.

23 Aug, 2022 | 13:26h | UTC

Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis – eClinicalMedicine

Related: Study: Cancer Patients with HIV Infection Have Worse Outcomes

 


Consensus Statement | Preoperative management of medications for rheumatologic and HIV diseases.

22 Aug, 2022 | 12:22h | UTC

Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Related:

Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases – Mayo Clinic Proceedings

Preoperative Management of Medications for Neurologic Diseases – Mayo Clinic Proceedings

Preoperative Management of Medications for Psychiatric Diseases: Society for Perioperative Assessment and Quality Improvement Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Gastrointestinal and Pulmonary Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Opioid and Nonopioid Analgesics: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Surgical Patients Using Dietary Supplements – Mayo Clinic Proceedings

Perioperative Evaluation and Management of Endocrine Disorders – Mayo Clinic Proceedings

Preoperative Cardiac Risk Assessment – Mayo Clinic Proceedings

Preoperative Evaluation Before Noncardiac Surgery – Mayo Clinic Proceedings

Perioperative Cardiac Risk Reduction in Noncardiac Surgery – Mayo Clinic Proceedings

Examining Risk: A Systematic Review of Perioperative Cardiac Risk Prediction Indices – Mayo Clinic Proceedings

Perioperative Venous Thromboembolism Prophylaxis – Mayo Clinic Proceedings

 


CDC interim guidance for prevention and treatment of Monkeypox in persons with HIV infection.

17 Aug, 2022 | 14:36h | UTC

Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022 – Morbidity and Mortality Weekly Report

 


Systematic Review | Accuracy of measures for antiretroviral adherence in people living with HIV.

17 Aug, 2022 | 14:11h | UTC

Accuracy of measures for antiretroviral adherence in people living with HIV – Cochrane Library

Summary: Are there good ways to find out if people living with HIV are taking their medicines every day? – Cochrane Library

 


M-A | Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV.

9 Aug, 2022 | 12:41h | UTC

Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis – eClinicalMedicine

 


RCT | 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy.

4 Aug, 2022 | 14:33h | UTC

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study – The Lancet HIV

Related:

WHO Recommends Dolutegravir as Preferred HIV Treatment Option in All Populations

Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.

RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

Randomized controlled trial compared three antiretroviral regimens started in pregnant women with HIV

Randomized Trial: Switching to Dolutegravir/Lamivudine Two-Drug Regimen Noninferior to Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1

 


Network M-A | Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy.

4 Aug, 2022 | 13:30h | UTC

Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy – a systematic literature review and network meta-analysis – eClinicalMedicine

 

Commentary on Twitter

 


WHO Guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations.

2 Aug, 2022 | 12:41h | UTC

Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations – World Health Organization

News Release: WHO publishes new guidelines on HIV, hepatitis and STIs for key populations – World Health Organization

 


M-A | Worldwide occurrence of HIV-associated neurocognitive disorders and its associated factors.

22 Jul, 2022 | 11:30h | UTC

Worldwide Occurrence of HIV-Associated Neurocognitive Disorders and Its Associated Factors: A Systematic Review and Meta-Analysis – Frontiers in Psychiatry

 


WHO Guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia.

5 Jul, 2022 | 12:22h | UTC

WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia – World Health Organization

News Release: Visceral leishmaniasis and HIV coinfection: WHO publishes new guideline with region-specific treatment recommendations – World Health Organization


WHO Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV.

5 Jul, 2022 | 12:23h | UTC

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV – World Health Organization


RCT: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half.

21 Jun, 2022 | 11:11h | UTC

News Release: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half – National Institutes of Health

Original Study: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


M-A: Benefits and risks of rapid initiation of antiretroviral therapy in patients with HIV.

21 Jun, 2022 | 10:41h | UTC

Benefits and Risks of Rapid Initiation of Antiretroviral Therapy: A Systematic Review and Meta-Analysis – Frontiers in Pharmacology

 


The global landscape of the burden of depressive symptoms/major depression in individuals living with HIV/AIDs and its effect on antiretroviral medication adherence.

10 Jun, 2022 | 10:31h | UTC

The Global Landscape of the Burden of Depressive Symptoms/Major Depression in Individuals Living With HIV/AIDs and Its Effect on Antiretroviral Medication Adherence: An Umbrella Review – Frontiers in Psychiatry

 


Combination anti-HIV antibody infusions suppress virus for prolonged period.

7 Jun, 2022 | 11:45h | UTC

News Release: Combination anti-HIV antibody infusions suppress virus for prolonged period – National Institutes of Health

Original Study: Combination anti-HIV antibodies provide sustained virological suppression – Nature

 

Commentaries on Twitter

 


Guidelines for the Kaposi Sarcoma.

6 Jun, 2022 | 11:20h | UTC

S1 Guidelines for the Kaposi Sarcoma – Journal of the German Society of Dermatology

 


Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.

16 May, 2022 | 01:41h | UTC

Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations – BMJ Open

 


Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19.

13 May, 2022 | 11:28h | UTC

Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 – The Lancet HIV

Invited Commentary: A collision of pandemics: HIV and COVID-19 – The Lancet HIV

 

Commentaries on Twitter

 


Capsid inhibition with Lenacapavir in multidrug-resistant HIV-1 infection.

12 May, 2022 | 10:20h | UTC

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Lenacapavir for HIV Infection in a Multidrug-Resistant Study Cohort – ContagionLive

 


M-A: Evaluation of HIV treatment outcomes with reduced frequency of clinical encounters and antiretroviral treatment refills.

12 May, 2022 | 08:04h | UTC

Evaluation of HIV treatment outcomes with reduced frequency of clinical encounters and antiretroviral treatment refills: A systematic review and meta-analysis – PLOS Medicine

 


Review: Hemophagocytic Lymphohistiocytosis in patients with HIV.

11 May, 2022 | 10:47h | UTC

A Review of Hemophagocytic Lymphohistiocytosis in Patients With HIV – Open Forum Infectious Diseases

 


Stay Updated in Your Specialty

No spam, just news.